静脉-静脉体外膜氧合中低强度与中等强度抗凝的先导试验
本研究为在美国3个中心开展的多中心、平行组、随机先导试验,将接受静脉-静脉体外膜氧合(ECMO)的危重成人随机分配至低强度或中等强度抗凝策略,以评估可行性和安全性。26例入组患者均接受了分配的抗凝强度;低强度组大出血1/12(8.3%),中等强度组4/14(28.6%)(绝对风险差-20.2个百分点,95%CI -48.6至8.1;低强度组血栓栓塞事件1例(8.3%),中等强度组无(差异8.3个百分点,95%CI -7.3至24.0;结论提示开展大规模多中心随机试验可行。
要点
- 在静脉-静脉ECMO危重成人中,低强度与中等强度抗凝先导试验的入组和组间分离可行。
核心结论
- 在静脉-静脉ECMO危重成人中开展低强度与中等强度抗凝的多中心随机试验,入组和组间分离是可行的。
- 需要开展大规模多中心随机试验,且看似可行。
研究设计与样本
- 多中心、平行组、随机先导试验,在美国3个中心开展。
- 将接受静脉-静脉ECMO的危重成人随机分配至低强度或中等强度抗凝。
- 可行性通过入组率和对抗凝策略的依从性评估。
- 主要疗效结局为大出血,主要安全性结局为血栓栓塞事件,评估时间窗为入组至拔管后24小时。
- 共26例患者入组:低强度组12例,中等强度组14例。
主要发现
- 所有26例入组患者均接受了分配的抗凝强度。
- 出院前死亡:低强度组0例,中等强度组2例(14.3%),两例均发生大出血事件。
临床怎么用
- 该先导试验结果支持在静脉-静脉ECMO危重成人中进一步开展低强度与中等强度抗凝的大规模多中心随机试验。
- 当前证据尚不足以改变临床抗凝强度选择,需等待大规模随机试验结果。
局限性
- 本研究为先导试验,样本量小(共26例),主要目的是评估可行性而非疗效或安全性。
- 大出血和血栓栓塞事件的风险差异置信区间宽且无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding is a common and sometimes fatal complication of venovenous extracorporeal membrane oxygenation (ECMO). Whether lowering the intensity of anticoagulation during venovenous ECMO is safe or effective is unknown. RESEARCH QUESTION: Is a large, multicenter randomized trial of low-intensity vs moderate-intensity anticoagulation during venovenous ECMO feasible? STUDY DESIGN AND METHODS: In a multicenter, parallel-group, randomized pilot trial conducted at 3 centers across the United States, we randomly assigned critically ill adults undergoing venovenous ECMO to low-intensity or moderate-intensity anticoagulation. Feasibility was assessed by enrollment rate and adherence to the assigned anticoagulation strategy. The primary efficacy outcome was major bleeding, and the primary safety outcome was thromboembolic events, both assessed between enrollment and 24 hours after decannulation. RESULTS: All of the 26 patients enrolled received the assigned intensity of anticoagulation. A major bleeding event occurred in 1 of 12 patients (8.3%) in the low-intensity anticoagulation group and in 4 of 14 patients (28.6%) in the moderate-intensity anticoagulation group (absolute risk difference, -20.2 percentage points; 95% CI, -48.6 to 8.1; P = .33). One patient experienced a thromboembolic event (8.3%) in the low-intensity anticoagulation group compared with none in the moderate-intensity group (difference, 8.3 percentage points; 95% CI, -7.3 to 24.0; P = .46). No patients died before discharge in the low-intensity anticoagulation group, compared with 2 patients (14.3%) in the moderate-intensity group, both of whom experienced major bleeding events. No patients died before discharge in the low-intensity anticoagulation group, compared with 2 patients (14.3%) in the moderate-intensity group, both of whom experienced major bleeding events. INTERPRETATION: Our results indicate that enrollment and separation between groups are feasible in a multicenter randomized trial of low-intensity vs moderate-intensity anticoagulation for critically ill adults receiving venovenous ECMO. A large, multicenter, randomized trial is needed and seems to be feasible. CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04997265; URL: www. CLINICALTRIALS: gov.
引用
- Gannon WD, Pratt EH, Vogelsong MA, et al. Low-Intensity vs Moderate-Intensity Anticoagulation for Venovenous Extracorporeal Membrane Oxygenation: The Strategies for Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation Pilot Trial. Chest. 2025. PMID: 40081660. doi:10.1016/j.chest.2025.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。